Insights are crucial for product success. In today’s competitive market, it’s essential to accurately identify and address unmet stakeholder needs. However, many companies struggle with siloed insights, duplication of effort, and poor internal alignment. Our white paper, “Insights and Patient Journeys: Building the Foundation of Effective Planning”, outlines a patient journey-based approach to organise and assess insights, informing strategy and brand planning. This helps to ensure that the patient remains central to the decision-making process, whilst also placing insights within the broader context of the treatment journey.

HCPs’ increasing reliance on the scientific expertise of MSLs is positioning the role as an essential strategic resource for Pharma companies. This trend has resulted in a boom in the number of MSLs across the industry – since 2010 MSL headcount has increased by 300%. However, many Medical Affairs teams remain underfunded and struggle to provide MSLs the support and resources they need to effectively carry out their impactful work. Oliver Spray has written a white paper titled “Empowering MSLs to deliver better scientific engagements”, which examines three challenges MSLs face in delivering impactful HCP engagements as well as providing proposals to Pharma on how to overcome them.

Pharmaceutical companies conduct evidence generation activities within Medical Affairs through Investigator Sponsored (ISS), Company Sponsored (CSS), and Collaborative Research Studies (CRS). The timely completion of these studies is vital to generate relevant evidence for the wider scientific community; and helps to ensure that studies complete on budget.

Over the course of the pandemic the use of Decentralised Clinical Trials (DCT) increased significantly, with around 87% of sponsors and contract research organisations conducting or planning to conduct trials with decentralised aspects – compared to 28% prior to the pandemic. The primary driver for this shift was to avoid delays in clinical trials that included vulnerable patients that were unwilling or unable to come onto site. As the adoption of trial decentralisation rises, a number of challenges have presented themselves…